Solid Biosciences Inc
SLDB
NASDAQ
Biotechnology
$9.20
USD
+0.12 (+1.32%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $976.82M
Volume 759.0K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-207.10M
TTM
-34.4%
YoY
Operating Cash Flow
$-186.84M
TTM
-52.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 9.3 | 9.2 | 11.3 | 11.2 | 13.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 41.7 | 48.1 | 49.4 | 57.3 | 57.4 |
Operating Income | -41.7 | -48.1 | -49.4 | -57.3 | -57.4 |
EBITDA | -41.3 | -47.7 | -48.9 | -56.9 | -57.0 |
Other Income / Expense | -0.7 | -0.6 | -2.4 | -1.5 | -0.6 |
Total Other Income / Expense | 2.2 | 2.3 | -0.4 | 0.6 | 2.6 |
Income Before Income Taxes | -39.5 | -45.8 | -49.8 | -56.7 | -54.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -39.5 | -45.8 | -49.8 | -56.7 | -54.8 |
Consolidated Net Income / Loss | -39.5 | -45.8 | -49.8 | -56.7 | -54.8 |
Net Income Attributable to Common Shareholders | -39.5 | -45.8 | -49.8 | -56.7 | -54.8 |
Basic EPS | -$0.42 | -$0.48 | -$0.52 | -$0.52 | -$0.38 |
Diluted EPS | -$0.42 | -$0.48 | -$0.52 | -$0.52 | -$0.38 |
Basic Shares Outstanding | 94.1M | 94.4M | 95.1M | 109.8M | 143.7M |
Diluted Shares Outstanding | 94.1M | 94.4M | 95.1M | 109.8M | 143.7M |